Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma. Benjamin DJ, Lythgoe MP, Rezazadeh A. BJU Int 2023;131:691-693.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Benjamin DJ, Lythgoe MP, Rezazadeh A. Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma. BJU Int 2023;131:691-693.
PMID: 36877951